Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase 3 Terminated
96 enrolled 16 charts
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
Phase 2 Terminated
30 enrolled 15 charts
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
Phase 3 Terminated
77 enrolled 11 charts
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
Phase 2 Terminated
7 enrolled 9 charts
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Phase 2 Terminated
175 enrolled 8 charts
S0502
Phase 3 Terminated
12 enrolled 13 charts
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2 Terminated
13 enrolled 13 charts
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Phase 3 Terminated
72 enrolled 15 charts
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Phase 2 Terminated
10 enrolled 6 charts
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Terminated
5 enrolled 7 charts
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Phase 1 Terminated
36 enrolled
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Phase 3 Terminated
2,200 enrolled
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
24 enrolled
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Terminated
120 enrolled
Bevacizumab and Irinotecan to Treat Brain Tumors
Phase 2 Terminated
31 enrolled 12 charts